Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.34 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | CHI3L1 | P36222 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.33 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | MLNR | O43193 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22554967 | 1.00 | SMYD2 (0.39) | SMYD2CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL31460034 | 0.96 | SMYD2 (0.38) | SMYD2CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL22554979 | 0.92 | SMYD2 (0.40) | SMYD2CYP3A4 | |
| SCHEMBL25906381 | 0.84 | CHRNB2 (0.50) | CHRNB2CHRNA5CHRNA7CHRNA4CHRNB4 | |
| SCHEMBL29945202 | 0.82 | CHRNB4 (0.43) | CHRNB2CHRNA5CHRNA7CHRNA4CHRNB4 | |
| SCHEMBL29875863 | 0.82 | CHRNB4 (0.43) | CHRNB2CHRNA5CHRNA7CHRNA4CHRNB4 | |
| SCHEMBL20534267 | 0.78 | FFAR1 (0.46) | SMYD2 | |
| SCHEMBL18786265 | 0.78 | FFAR1 (0.46) | SMYD2 | |
| SCHEMBL30805383 | 0.78 | SMYD2 (0.36) | SMYD2CYP3A4 | |
| SCHEMBL23665772 | 0.77 | CASP3 (0.36) | SMYD2CHRNB2CHRNA5CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112047939-B | Tetrahydropyridopyrimidine compound with anti-tumor activity | 江苏先声药业有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4087573-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| CN-115181106-A | Quinazoline KRAS G12D Preparation and application of mutant protein inhibitor | 药雅科技(上海)有限公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-115073451-A | KRAS G12D Preparation and application of mutant protein inhibitor | 药雅科技(上海)有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-112047939-A | Tetrahydropyridopyrimidine compound with anti-tumor activity | 江苏先声药业有限公司 | 2020-12-08 | — | — | CN | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | SMYD2 3495/4885CHRNB2 4856/4885CHRNA5 4867/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | SMYD2 3495/4885CHRNB2 4856/4885CHRNA5 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.